METHOD OPTIMIZATION FOR KETOPROFEN TABLET DISSOLUTION: ENHANCED EFFICIENCY THROUGH MODIFIED TEST CONDITIONS
Keywords:
ketoprofen, spectrophotometric methods, dissolutionAbstract
The continuous advancement of the pharmaceutical industry is not only marked by the discovery of novel therapeutic agents and innovative dosage forms but also by the need to improve existing analytical methodologies, especially those involved in process quality control. In modern pharmaceutical development, rapid, cost-effective, and reliable analytical techniques are essential to ensure the consistent performance and therapeutic efficacy of marketed drug products. One of the critical parameters in evaluating the bioavailability and therapeutic potential of solid oral dosage forms is their dissolution behavior, which directly correlates with drug solubility under physiologically relevant conditions. This research paper focuses on the optimization and modification of an existing UV-Vis spectrophotometric method for testing the dissolution of ketoprofen in tablet formulations, with the goal of simplifying and accelerating the dissolution testing protocol. The study involved the deliberate modification of several test conditions, including the pH of the dissolution medium (adjusted from pH 7.2 to pH 6.8), the rotation speed (reduced from 100 rotations per minute (rpm) to 75 rpm), and the sampling time points (shifted from a single 45 minute time point to three intervals of 15, 30, and 45 minutes). The choice of these parameters was based on their relevance to both physiological conditions and analytical efficiency. The results demonstrated that the modified method produced more favorable dissolution profiles, with significantly improved average solubility of the active pharmaceutical ingredient (API) even after just 15 minutes of testing. Such a rapid and consistent dissolution rate not only ensures better prediction of in vivo behavior but also offers a practical advantage for routine quality control testing by reducing analysis time without compromising reliability. Furthermore, this study highlights the need for ongoing evaluation and refinement of existing pharmacopoeia methods, recognizing that established procedures may benefit from scientifically supported improvements. The findings support a more flexible approach to method development, where alternative techniques when properly validated in line with official pharmacopeia standards can be considered for routine use. The study also emphasizes the broader relevance of method optimization in pharmaceutical analysis, demonstrating how minor but deliberate modifications to test conditions can lead to meaningful improvements in accuracy, speed, and efficiency. In conclusion, the proposed dissolution testing method presents a viable and promising alternative for the routine analysis of ketoprofen tablets, offering enhanced operational efficiency, practical utility, and alignment with modern industry demands for rapid, reliable, and cost-effective quality control strategies.
References
Abdulrahman A. Alagga, Mark V. & Pellegrini, V. G. (2024). Drug Absorption. https://www.ncbi.nlm.nih.gov/books/NBK557405/
European Pharmacopoeia, 11th Edition (2023). Ketoprofen monograph. Council of Europe, Strasbourg.
Gan, Y., Baak, J. P. A., Chen, T., Ye, H., Liao, W., Lv, H., Wen, C., & Zheng, S. (2023). Supersaturation and Precipitation Applicated in Drug Delivery Systems: Development Strategies and Evaluation Approaches. Molecules, 28(5). https://doi.org/10.3390/molecules28052212
Jamali, F., & Brocks, D. R. (1990). Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers. Clinical Pharmacokinetics, 19(3), 197–217. https://doi.org/10.2165/00003088-199019030-00004
Kantor, T. G. (1986). Ketoprofen: A Review of Its Pharmacologic and Clinical Properties. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 6(3), 93–102. https://doi.org/10.1002/j.1875-9114.1986.tb03459.x
Kumar, B., Sahani, V., & Patil, S. (2024). Review on Ketoprofen (Anti-Inflammatory Drug). Journal for Research in Applied Sciences and Biotechnology, 3(6), 41–50. https://doi.org/10.55544/jrasb.3.6.6
Liversidge G.G. (1981). Ketoprofen. Analytical Profiles of Drug Substances and Excipients, 10, 443–471. https://doi.org/10.1016/S0099-5428(08)60647-4
Mazumder, K., Hossain, M. E., Aktar, A., Mohiuddin, M., Sarkar, K. K., Biswas, B., Aziz, M. A., Abid, M. A., & Fukase, K. (2021). In silico analysis and experimental evaluation of ester prodrugs of ketoprofen for oral delivery: With a view to reduce toxicity. Processes, 9(12). https://doi.org/10.3390/pr9122221
Muenster, U., Pelzetter, C., Backensfeld, T., Ohm, A., Kuhlmann, T., Mueller, H., Lustig, K., Keldenich, J., Greschat, S., Göller, A. H., & Gnoth, M. J. (2011). Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): Tools to predict in vivo bioavailability from orally applied drug suspensions. European Journal of Pharmaceutics and Biopharmaceutics, 78(3), 522–530. https://doi.org/10.1016/j.ejpb.2011.01.023
Nashed, N., Chan, S., Lam, M., Ghafourian, T., & Nokhodchi, A. (2023). Effect of pH, Ionic Strength and Agitation Rate on Dissolution Behaviour of 3D-Printed Tablets, Tablets Prepared from Ground Hot-Melt Extruded Filaments and Physical Mixtures. Biomedicines, 11(2). https://doi.org/10.3390/biomedicines11020375
National Center for Biotechnology Information. (n.d.). PubChem Compound Summary for CID 3825, Ketoprofen. Retrieved July 31, 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/R_-Ketoprofen
Petrie, B., & Camacho-Muñoz, D. (2021). Analysis, fate and toxicity of chiral non-steroidal anti-inflammatory drugs in wastewaters and the environment: a review. In Environmental Chemistry Letters (Vol. 19, Issue 1). Springer International Publishing. https://doi.org/10.1007/s10311-020-01065-y
Rahman, M. S., Yoshida, N., Tsuboi, H., Ishii, Y., Akimoto, Y., & Kimura, K. (2021). Small-scale dissolution test screening tool to select potentially substandard and falsified (SF) medicines requiring full pharmacopoeial analysis. Scientific Reports, 11(1), 1–9. https://doi.org/10.1038/s41598-021-91443-5
RxReasoner. (n.d.). ATC Group: M02AA10 Ketoprofen. Retrieved July 28, 2025, from https://www.rxreasoner.com/atccodes/M02AA10
